India Tirzepatide Market Analysis The India Tirzepatide market is estimated to be valued at USD 2.8 million in 2026 and is expected to reach USD 7.4 million by 2032, exhibiting a compound annual growth rate (CAGR) of 15.2% from 2026 to 2032
Together, these effects not only support steady weight reduction but also improve underlying metabolic conditions that often accompany obesity
Now, FDA enforcement is going after pharmacies that make copies of drugs which are already on the market, unless there is a real medical reason
Unlike other GLP-1s, tirzepatide is actually a combination of two hormones (GLP-1 and GIP), which may lead to even greater results
These numbers come from the SURMOUNT-1 trial, which enrolled over 2,500 adults with obesity or overweight and tracked outcomes for 72 weeks
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease